Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625270 · ClinicalTrials.gov registry record · Phase 2
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
A Phase 2 study of Ovarian Cancer and Low Grade Ovarian Serous Adenocarcinoma, sponsored by Verastem.
- Active
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT04625270 is a Phase 2 study of Ovarian Cancer and Low Grade Ovarian Serous Adenocarcinoma that is active but no longer recruiting, run by Verastem. The registered enrollment target is 225 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT04625270, a Phase 2 study of Ovarian Cancer and Low Grade Ovarian Serous Adenocarcinoma, is active but no longer recruiting, sponsored by Verastem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Conditions Studied
Interventions
- DRUG avutometinib (VS-6766)
- DRUG avutometinib (VS-6766) and defactinib
Study Locations (20)
Florida
- Advent Health - Orlando
- H. Lee Moffitt Cancer Center and Research Institute - Center for Women's Oncology - Tampa
Ohio
- Cleveland Clinic Women's Health Institute - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Oregon
- Willamette Valley Cancer Institute and Research Center - Eugene
- Northwest Cancer Specialists - Portland
Texas
- Texas Oncology Austin Central - Austin
- Texas Oncology- Dallas Presbyterian Hospital - Dallas
Arizona
- Arizona Oncology Associates PC HAL - Scottsdale
California
- Sansum Clinic - Santa Barbara
Connecticut
- Yale School of Medicine - New Haven
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04625270
The ClinicalTrials.gov registry entry for NCT04625270 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which avutometinib (VS-6766) is the first listed.
NCT04625270 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT04625270 about?
NCT04625270 is a clinical study titled "A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation". This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
What is the current status of trial NCT04625270?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2020-12-21. Estimated completion is 2026-12.
What conditions does trial NCT04625270 study?
This clinical trial studies the following conditions: Ovarian Cancer, Low Grade Ovarian Serous Adenocarcinoma.
What interventions are being tested in trial NCT04625270?
The interventions under investigation include: avutometinib (VS-6766) (DRUG), avutometinib (VS-6766) and defactinib (DRUG).
Who is sponsoring clinical trial NCT04625270?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04625270 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.